Pharmacokinetics and pharmacodynamics of depot medroxyprogesterone acetate in african women receiving treatment for human immunodeficiency virus and tuberculosis: Potential concern for standard dosing frequency

Rosie Mngqibisa*, Michelle A. Kendall, Kelly Dooley, Xingye Wu, Cynthia Firnhaber, Helen McIlleron, Jennifer Robinson, Yoninah Cramer, Susan L. Rosenkranz, Jhoanna Roa, Kristine Coughlin, Sajeeda Mawlana, Sharlaa Badal-Faesen, David Schnabel, Ayotunde Omoz-Oarhe, Wadzanai Samaneka, Catherine Godfrey, Susan E. Cohn

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background. Effective contraception is critical to young women with HIV-associated tuberculosis (TB), as unintended pregnancy is associated with increased perinatal morbidity and mortality. The effects of co-administration of efavirenz and rifampicin on the pharmacokinetics of depot medroxyprogesterone acetate (DMPA) are unknown. We hypothesized that clearance of medroxyprogesterone acetate (MPA) would increase when given with rifampicin and efavirenz, thus increasing risk of ovulation. Methods. This pharmacokinetics (PK) study assessed DMPA among HIV/TB coinfected women on an efavirenz-based antiretroviral treatment and rifampicin-based TB treatment. Plasma MPA concentrations and progesterone were measured predose (MPA only) and 2, 4, 6, 8, 10, and 12 weeks after a single DMPA 150 mg intramuscular injection. The primary outcome measure, MPA concentration (<0.1 ng/mL) at week 12, was assessed using exact 95% Clopper-Pearson confidence intervals. MPA PK parameters were calculated using noncompartmental analysis. Results. Among 42 PK-evaluable women from 5 African countries, median age was 32 years and median CD4 was 414 cells/ mm3. Five women (11.9%; 95% CI, 4.0-25.6%) had MPA <0.1 ng/mL at week 12; of these, one had MPA <0.1 ng/mL at week 10. The median clearance of MPA was 19 681 L/week compared with 12 118 L/week for historical controls. There were no adverse events related to DMPA, and progesterone concentrations were <1 ng/mL for all women for the study duration. Conclusions. DMPA, when given with rifampicin and efavirenz, was safe. MPA clearance was higher than in women with HIV not on ART, leading to subtherapeutic concentrations of MPA in 12% of women, suggesting that more frequent dosing might be needed.

Original languageEnglish (US)
Pages (from-to)517-524
Number of pages8
JournalClinical Infectious Diseases
Volume71
Issue number3
DOIs
StatePublished - Aug 1 2020

Keywords

  • DMPA
  • Efavirenz
  • HIV
  • Rifampicin
  • Tuberculosis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pharmacokinetics and pharmacodynamics of depot medroxyprogesterone acetate in african women receiving treatment for human immunodeficiency virus and tuberculosis: Potential concern for standard dosing frequency'. Together they form a unique fingerprint.

Cite this